Submit to Nutrients Review for Nutrients Propose a Special Issue

Journal Browser

► Journal Browser

Clinical Nutrition in the Management of Irritable Bowel Syndrome

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Clinical Nutrition".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 12937

Share This Special Issue

Special Issue Editor

Prof. Dr. Peter C. Konturek

E-Mail Website
Guest Editor

Thuringia Clinic Saalfeld, Teaching Hospital of the University of jena, 07318 Saalfeld, Germany
Interests: irritable bowel syndrome; gut microbiota; food intolerance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Irritable Bowel Syndrome (IBS) represents the most common functional disorder of the gastrointestinal tract characterized by chronic or recurrent abdominal pain associated with altered bowel habits. The diferential diagnosis of IBS is very broad an include celiac disease, multiple food intolerances, food allergies colorectal cancer, neuroendocrine tumor, inflammatory bowel disaease, ischemic colitis, pancreatic insufficiency , small intestinal bacterial overgrowth, psychiatric disorders and others.

The management of IBS is multifaceted including general measures, pharmacological therapy, diet (FODMAP-low diet), microbiota-modulating therapy (pre- pro- and synbiotics, fecal microbiota therapy) and complementary alternative therapies.

This issue is focused on the new developments in the diagnosis and treatment of IBS and the role of nutritional management in the treatment of this disease.

Prof. Dr. Peter C. Konturek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

irritable bowel syndrome
microbiota-gut-brain axis
microbial
metabolites
COVID-19
histamine
mast cells
tryptase
histamine intolerance
motility
visceral pain
food allergy
food intolerance
FODMAP
therapy

Published Papers (3 papers)

Download All Papers

Research

Jump to: Review

12 pages, 1296 KiB

Open AccessArticle

Blueberries Improve Abdominal Symptoms, Well-Being and Functioning in Patients with Functional Gastrointestinal Disorders

by Clive H. Wilder-Smith, Andrea Materna and Søren S. Olesen

Nutrients 2023, 15(10), 2396; https://doi.org/10.3390/nu15102396 - 20 May 2023

Cited by 1 | Viewed by 2998

Abstract

Blueberries beneficially modulate physiologic mechanisms relevant to the pathogenesis of functional gastrointestinal disorders (FGID). Forty-three patients with FGID received freeze-dried blueberries (equivalent to 180 g fresh blueberries) or sugar and energy-matched placebo in a double-blind, randomized, cross-over study. After 6 weeks of treatment, the differences in Gastrointestinal Clinical Rating Scale (GSRS) scores and abdominal symptom relief were compared as primary outcome measures. The quality of life and life functioning ratings (OQ45.2 questionnaire), Bristol stool scales, and fructose breath test results constituted secondary outcome measures. Blueberry treatment resulted in more patients with relevant abdominal symptom relief compared to placebo (53% vs. 30%, p = 0.03). Total and pain GSRS scores improved insignificantly (mean treatment differences [95% CI]: −3.4 [−7.4 to 0.6] (p = 0.09) and −1.0 [−2.2 to 0.1] (p = 0.08), respectively). OQ45.2 scores improved during blueberry treatment compared to placebo (treatment difference −3.2 [95% CI: −5.6 to −0], p = 0.01). Treatment effect differences for the further measures did not reach statistical significance. Blueberries relieved abdominal symptoms and improved general markers of well-being, quality of life, and life functioning more than placebo in patients with FGID. Consequently, the polyphenol and fiber components of blueberries exert broad beneficial effects separate from the sugars present in both treatments. Full article

(This article belongs to the Special Issue Clinical Nutrition in the Management of Irritable Bowel Syndrome)

► Show Figures

Figure 1

13 pages, 1765 KiB

Open AccessArticle

Two Gold Kiwifruit Daily for Effective Treatment of Constipation in Adults—A Randomized Clinical Trial

by Simone B. Bayer, Phoebe Heenan, Chris Frampton, Catherine L. Wall, Lynley N. Drummond, Nicole C. Roy and Richard B. Gearry

Nutrients 2022, 14(19), 4146; https://doi.org/10.3390/nu14194146 - 6 Oct 2022

Cited by 3 | Viewed by 5696

Abstract

Chronic constipation is highly prevalent worldwide and may be managed with two green or three gold kiwifruit daily. It is unknown whether a smaller standard serve of gold kiwifruit (two daily) is as effective in constipation management. The study aimed to improve chronic constipation with two gold kiwifruit and psyllium in lieu of a placebo daily over four weeks. Adult participants (18–65 years) with functional constipation (FC, n = 11), constipation-predominant irritable bowel syndrome (IBS-C, n = 13), and healthy controls (n = 32) were block-randomized to the treatment order: gold kiwifruit (2/day) or psyllium (fiber-matched, 7.5 g/day) for four weeks, followed by four weeks washout before crossover. Outcomes included alterations of Gastrointestinal Symptom Rating Scale (GSRS) domains and weekly complete spontaneous bowel movements (CSBM) as part of a larger study. Both interventions reduced GSRS constipation domain scores in all subjects compared to baseline values (p = 0.004). All participants reported significantly more weekly CSBM (p = 0.014). Two gold kiwifruit decreased straining (p = 0.021). Two gold kiwifruit daily are as effective as fiber-matched psyllium in treating constipation in adults and should be considered as a treatment option. Full article

(This article belongs to the Special Issue Clinical Nutrition in the Management of Irritable Bowel Syndrome)

► Show Figures

Figure 1

Review

Jump to: Research

21 pages, 665 KiB

Open AccessReview

Effects of a Low-FODMAP Diet on Irritable Bowel Syndrome in Both Children and Adults—A Narrative Review

by Ionela-Daniela Morariu, Liliana Avasilcai, Madalina Vieriu, Vasile Valeriu Lupu, Branco-Adrian Morariu, Ancuța Lupu, Paula-Cristina Morariu, Oana-Lelia Pop, Iuliana Magalena Starcea and Laura Trandafir

Nutrients 2023, 15(10), 2295; https://doi.org/10.3390/nu15102295 - 13 May 2023

Cited by 7 | Viewed by 3787

Abstract

Irritable bowel syndrome is a typical gastrointestinal disease that causes bloating, flatulence, abdominal pain, diarrhoea, constipation, or alteration of the last two in adults and children. A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) is one of the potential treatment strategies to reduce abdominal symptoms and increase the quality of life. The present narrative review aims to present a general overview of current studies that have evaluated the efficacy of a low-FODMAP diet against other diets in gastrointestinal symptoms, nutrient intake in adults and children, and lifestyle quality. The research was performed using seven searchable databases, which included the Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Excerpta Medica Database (EMBASE), Medline, PubMed, Scopus, and Web of Science, up to March 2023. In conclusion, there is significant evidence that the follow-up of a low-FODMAP diet might be a feasible first-line therapeutic strategy to reduce stomach discomfort, pain, bloating, and quality of life for patients with irritable bowel syndrome. Full article

(This article belongs to the Special Issue Clinical Nutrition in the Management of Irritable Bowel Syndrome)

► Show Figures